Proteins

Product Data Sheet

VSIG2 Protein, Human (HEK293, His)

Cat. No.: HY-P70503

Synonyms: V-Set and Immunoglobulin Domain-Containing Protein 2; Cortical Thymocyte-Like Protein; CT-

Like Protein; VSIG2; CTH; CTXL

Species: Human Source: **HEK293**

Accession: Q96IQ7 (V24-A243)

Gene ID: 23584 Molecular Weight: 29-35 kDa

PROPERTIES

AA Sequence				
	VEVKVPTEPL	STPLGKTAEL	$T\;C\;T\;Y\;S\;T\;S\;V\;G\;D$	SFALEWSFVQ
	PGKPISESHP	ILYFTNGHLY	PTGSKSKRVS	LLQNPPTVGV
	ATLKLTDVHP	SDTGTYLCQV	NNPPDFYTNG	LGLINLTVLV
	PPSNPLCSQS	GQTSVGGSTA	LRCSSSEGAP	KPVYNWVRLG
	TFPTPSPGSM	VQDEVSGQLI	LTNLSLTSSG	TYRCVATNQM
	GSASCELTLS	VTEPSQGRVA		

Appearance Lyophilized powder.

Formulation Lyophilized from a 0.2 µm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.2.

Endotoxin Level <1 EU/ μ g, determined by LAL method.

Reconsititution It is not recommended to reconstitute to a concentration less than $100 \, \mu g/mL$ in ddH_2O . For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

V-set and immunoglobulin domain-containing protein 2, also known as corticothymocyte-like protein, CT-like protein and VSIG2, is a single-generation type I membrane protein. VSIG2 is highly expressed in the stomach and colon and weakly expressed in the bladder and lungs. VSIG2 is associated with immune invasion and antigen presentation of colon cancer (COAD), and it can be used as a potential biomarker or therapeutic target for COAD. VSIG2 promotes the malignant progression of pancreatic ductal adenocarcinoma through LAMtor2-mediated mTOR activation. VISG2 has been associated with a variety of diseases, in corneal samples from Fuchs patients with endothelial corneal dystrophy (FECD), in intestinal

biopsies from patients with irritable bowel syndrome (IBS-D), in plasma from patients with acute tubule injury and interstitial fibrosis/tubular atrophy, and in plasma from patients with sudden heart failure. VSIG2 was found to be significantly upregulated [1][2][3].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com